Bradley Canino
Stock Analyst at Stifel
(1.75)
# 3,092
Out of 4,722 analysts
90
Total ratings
28.21%
Success rate
-8.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $50.82 | +126.29% | 2 | Dec 3, 2024 | |
| AFMD Affimed | Maintains: Hold | $5 → $4 | $1.19 | +236.13% | 5 | Nov 15, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $13.81 | +196.89% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $7.78 | +144.22% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $12.70 | +230.71% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $18.82 | +112.54% | 4 | Sep 25, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Buy | $28 | $4.83 | +479.71% | 4 | Sep 16, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $78.25 | +72.52% | 4 | Sep 16, 2024 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $20 | $8.50 | +135.29% | 1 | Sep 6, 2024 | |
| ALXO ALX Oncology Holdings | Reiterates: Hold | $5 → $3 | $1.85 | +62.16% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.61 | +521.12% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.78 | +259.71% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $42.23 | +134.43% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $3.84 | +264.58% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $68 | $19.82 | +243.09% | 5 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $11.13 | +259.39% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $90.63 | +43.44% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $40.52 | +35.74% | 4 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $10 | $2.03 | +392.61% | 4 | Jun 30, 2023 |
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $50.82
Upside: +126.29%
Affimed
Nov 15, 2024
Maintains: Hold
Price Target: $5 → $4
Current: $1.19
Upside: +236.13%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $13.81
Upside: +196.89%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $7.78
Upside: +144.22%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $12.70
Upside: +230.71%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $18.82
Upside: +112.54%
Relay Therapeutics
Sep 16, 2024
Reiterates: Buy
Price Target: $28
Current: $4.83
Upside: +479.71%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $78.25
Upside: +72.52%
ORIC Pharmaceuticals
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $8.50
Upside: +135.29%
ALX Oncology Holdings
Aug 9, 2024
Reiterates: Hold
Price Target: $5 → $3
Current: $1.85
Upside: +62.16%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.61
Upside: +521.12%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.78
Upside: +259.71%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $42.23
Upside: +134.43%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $3.84
Upside: +264.58%
May 8, 2024
Maintains: Buy
Price Target: $72 → $68
Current: $19.82
Upside: +243.09%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $11.13
Upside: +259.39%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $90.63
Upside: +43.44%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $40.52
Upside: +35.74%
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $2.03
Upside: +392.61%